Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (69184)	5/19/2002 3:11:58 PM
From: Zeev Hed	Read Replies (2) \| Respond to of 99280

The problem with Amevive, is not only the very rare occurrence of nasty side effects, but the mere fact that plagues all new psoriasis drugs, the almost impossible task of overcoming the placebo effect. Placebo in psoriasis is effective 25% , a huge numbers, in the last few years, I think at least ten drugs targeted for psoriasis failed to pass mustard with the FDA (Abgenix was last week's victim). My bet is Amevive does not get approved, and BGEN get beaten down. I'll wait to see how bad before reinstating my own OB (it was at $35.88 #reply-17485192) Zeev